

## **Sajeve Samuel Thomas**

### **Present Mailing Address**

1814 Lake Roberts Ct  
Windermere FL 34786  
Preferred Phone: 9546637551  
Alternate Phone: 9546639740

[askmedoncmd@gmail.com](mailto:askmedoncmd@gmail.com)  
[www.medoncmd.com](http://www.medoncmd.com)



### **Advent Health Cancer Institute – Downtown Orlando**

12/2025 – Present

Director of Cutaneous/Connective Tissue Malignancies & Solid Tumor Cellular Therapies

### **Medical Oncologist Locum**

General Hematology/Medical Oncology

4/2025 – 11/2025 - CAMC Teays Valley West Virginia via MyWeatherby

11/2024 – 4/2025 - St Vincent Billings Montana via Hayes Locum

### **Medical Oncology Consultant**

VA Audit – audit and provide opinion on standard of care for VA patients

Dane Street – healthcare utilization, disability review

Unum – healthcare utilization

NMR – healthcare utilization

Cimro – healthcare utilization

### **Director of Solid Tumor Cellular Therapy TIL –Cutaneous/Sarcomas**

- Orlando Health Cancer Institute at Orlando Health
- 8/2022 – Present
- Section Lead Cutaneous/Connective Tissue Malignancy Section 13 years
- 12 years' experience with Gastrointestinal Malignancies
- Championed TIL, OHCI is a TIL ATC
- TIL Treatment Metastatic Melanoma x 7 years
- TIL EAP 1<sup>st</sup> Global to open and most enrolled/treated 30+ patients
- OHCI is one of 30 sites across the country to deliver TIL commercially.
- Procedures with TVEC, pIL-12/RE, TLR9 agonist, Viral therapies Herpes, Polio.
- Solid Tumor Cellular Therapy TIL or TCR T Cell Clinical Trials with Iovance, Tscan, Tbio, Obsidian, Adaptimmune treated Gyn, GI malignancies, \$6-7 million in research grants
- DWG Section Lead for Cutaneous/Sarcoma - management a large team of research coordinators, data managers, regulatory coordinators, research pharmacist
- Melanoma/Sarcoma Tumor board biweekly 13 years
- Gastrointestinal and Colorectal Tumor board weekly x 12 years
- Principal Investigator Phase I/II/III clinical trials using bispecifics, mRNA, cytokines, cellular therapies, targeted therapies, immunotherapies, combination chemotherapies
- Speaker – Grand Grounds for OHCI, Grand Rounds University of Miami Dermatology, Annual Fellow's conference Melanoma, Soft Tissue Sarcoma, Bone Sarcomas, Journal Club
- 2024 ASCO Oral Abstract Melanoma Presenter – Iovance Phase II TIL/Pembro

**Medical Oncology Blog site [www.MedOncMD.com](http://www.MedOncMD.com)**

To bring awareness to actively enrolling clinical trials and distill medical oncology information to patients, caregivers, and healthcare providers

[www.medoncmd.com](http://www.medoncmd.com)

**Medical Oncologist –Cutaneous/Sarcomas/Gastrointestinal Malignancies**

Section Lead Cutaneous/Connective Tissue Malignancy Section  
Orlando Health Cancer Institute at Orlando Health  
8/2011 – 11/2024

**Clinical Investigator – Cutaneous/Sarcomas/Gastrointestinal Malignancies**

Orlando Health Cancer Institute at Orlando Health  
Phase I/II/III clinical trials  
2014 - Present

**Clinical Investigator – Melanoma/GI Section**

MD Anderson Cancer Center Orlando  
8/2011 – 2014

**Medical Oncology/Hematology Expert Witness**

2013 – Present – mostly causation opinions, few standard of care opinions

**Foundation One Genomic Tumor Board (National and International)**

Medical Oncology consultant  
2018-2021

**Medical Oncology Consultant – Speaker**

BMS, Merck, Ipsen, Novartis, Array, Amgen, Genentech, Springwork, Natera  
Advisory boards with Merck, Novartis, BMS, Pfizer  
2013 – Present

**UCF College of Medicine Assistant Professor**

University of Central Florida, Orlando  
10/2011 – Present

**FSU College of Medicine Assistant Professor**

University of Central Florida, Orlando  
10/2011 – Present

**Chief Fellow - Hematology/Oncology**

University of Florida, Gainesville, Florida  
7/2010 – 6/2011

**Board Review Coordinator Hematology-Oncology**

University of Florida, Gainesville, Florida  
7/2009– 6/2011

**Hematology/Oncology Fellowship**

University of Florida, Gainesville, Florida  
7/2008 – 6/2011

**Internal Medicine Residency**

University of South Florida IM, Tampa, Florida  
7/2005 – 6/2008

**Medical Education**

University of Florida College of Medicine, Gainesville, Florida  
Medical Doctorate  
7/2001 - 6/2005

**Undergraduate**

University of South Florida, Tampa, FL

B.A. Computer Science  
8/1997 - 6/2001

**Dual Enrollment**

Broward Community College, Davie, FL  
1/1997 - 5/1997

**Enrollment at our Site 2022-2023 – Top enrollment for Melanoma and GI**

Disease Working Group		Treatment		Early Phase Treatment		Radiation Treatment		Treatment Totals		Non-Treatment		Biorepository		Disease Working Group		All Facilities	
		2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023
Breast		2	4	---	---	---	16	2	20	14	11	1	4	Breast		17	35
Gastrointestinal		5	7	2	7	1	---	8	14	6	3	2	4	Gastrointestinal		14	21
Genitourinary		1	1	---	---	---	---	1	1	29	15	---	---	Genitourinary		30	16
Gynecology		---	2	---	---	---	---	---	2	---	---	---	---	Gynecology		---	2
Head-Neck		13	7	---	---	1	---	14	8	6	14	1	4	Head-Neck		21	26
Hematology		4	---	---	---	---	1	4	---	1	---	1	---	Hematology		6	---
Melanoma		35	26	2	19	---	---	37	45	16	14	---	2	Melanoma		53	61
Neurological		2	1	---	---	---	---	2	1	25	12	1	---	Neurological		28	13
Obsidian		---	---	---	---	---	---	---	---	---	---	---	6	Obsidian		---	6
Other		---	---	---	---	---	---	---	---	5	43	---	---	Other		5	43
Sarcoma		---	3	---	---	---	---	---	3	---	---	---	---	Sarcoma		---	3
Thoracic		2	1	---	2	---	---	2	3	36	48	4	3	Thoracic		42	54
<b>Totals</b>		<b>64</b>	<b>52</b>	<b>4</b>	<b>28</b>	<b>2</b>	<b>17</b>	<b>70</b>	<b>97</b>	<b>138</b>	<b>160</b>	<b>10</b>	<b>23</b>	<b>Totals</b>		<b>218</b>	<b>280</b>

**Orlando Health Cancer Institute is one of the initial 30 ATC Authorized Treatment Centers to Deliver TIL to Metastatic Melanoma patients.**

Showing Results for united states


united states

SEARCH AGAIN

PRINT RESULTS

Orlando Health Cancer Institute 1019.4 Miles  
1400 S Orange Ave  
ORLANDO, FL 32806  
321-841-1893

MedStar Georgetown University Hospital 1020.7 Miles  
3800 Reservoir Rd., NW  
WASHINGTON, DC 20007  
202-993-0492



## School Awards & Membership in Honorary/Professional Societies

NANET - member  
 NSABP - member  
 American Society of Hematology - Member  
 American Society of Clinical Oncology - Member  
 American College of Physicians  
 Outstanding Resident Award USF  
 Residents and Fellows of Indian Origin, Tampa Bay Chapter  
 Golden Key National Honor Society

## Certification/Licensure

Diagnosis and Management of Coagulation Disorders 12/04/08  
 Fully licensed in state of Florida 7/08  
 ACLS Certified 7/07

## Examinations

Hematology and Oncology Board Certified 11/2012  
 Hematology In-Service Exam 2/2010 - **90<sup>th</sup> Percentile**  
 Oncology In-Service Exam 3/2010 - **90<sup>th</sup> Percentile**  
 American Board of Internal Medicine 8/08 - Passed / Board Certified  
 USMLE Step 3 8/2007  
 USMLE Step 2 CS (Clinical Skills) 1/2005  
 USMLE Step 2 CK (Clinical Knowledge) 11/2004  
 USMLE Step 1 6/2003

## Awards/Accomplishments

Patient KIOSK Improved Perception Waiting- 2014  
 Clinical scribe - piloted first with improved clinic efficiency, notes, staging, orders  
 Narrative templates - improved pt oncology summary, billing, coding, presentation  
 ASCO Conquer Cancer Mentor Award 6-7/2012  
 Pfizer Drug Development Simulation - Program Manager for the Winning Team  
 Hem/Onc Pharmacology Jeopardy - 1<sup>st</sup> Place  
 Outstanding Resident Award - Distinction given to only 10% of our class  
 Dean's List Four Consecutive Years  
 Engineering Dean's List  
 USF Scholar Award by USF Honor's Program  
 Golden Key National Honor Society Scholar

## Publications

Lifileucel, a Tumor-infiltrating Lymphocyte Therapy, in Metastatic Melanoma.  
 • JCO 2021  
 Efficacy and safety of lifileucel a one-time autologous tumor infiltrating lymphocyte TIL cell therapy, in patients with advanced melanoma after progression on immune checkpoint

inhibitors and targeted therapies,: pooled analysis of consecutive cohorts C144-01

- Journal of Immunotherapy Cancer 2022

Individualized neoantigen therapy mRNA-4157 V940 plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma Keynote 942: a randomized phase 2b study

- Lancet 2024

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

- J Immunotherapy Cancer 2021

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab ovitecan, for the Treatment of Diverse Metastatic Solid Tumor.

- Clin Cancer Res 2015 Sep 1;21(17):3870-8 PMID: 25944802

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.

- Clin Cancer Res 2020 May. PMID: 31980466

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.

- J Immunother Cancer 2016 Aug PMID: 27532019

Melanoma/Sarcoma Rotational Curriculum for MDACCO Fellowship Program

"Institutional Review In The Treatment of Bladder/Upper Urinary Tract Malignancies"

*Retrospective review*

"Updated Review In the Management of Patients With Metastatic Brain Disease" Published in *Current Oncology*

Case Report: "Unique Polymorphism of Low Cytochrome b5 Expression in a Patient With Methemoglobinemia" submitted to the Journal of Clinical Pharmacology

### **Volunteer Experience**

3/2012 – Metro Church Health Fair – Panelist

7/2009 – 6/2010 Hematology/Oncology Board Review Coordinator

7/2008 – 6/2010 Medical Student Preceptor for Hematology/Oncology Education

8/2001 - 5/2005 Equal Access Clinic – Indigent Care Clinic

8/1999 - 5/2001 Golden Key National Honor Society Webmaster

8/1998 - 5/1999 Minority Pre-Professional Science Society – Vice President

1/1996 - 5/1997 IPC Church of God - Youth Coordinator and Pianist

### **Research**

*Principal Investigator*

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

*Principal Investigator*

OMS-I103-- The Pisces Study: A Multicenter phase 2, open-label trial of Intratumoral Tavokinogene Telseplasmid (tavo, PIL-12) plus Electroporation in combination with intravenous Pembrolizumab in patients with stage III/IV Melanoma who are progressing on either Pembrolizumab or Nivolumab treatment

*Principal Investigator*

C-144-01- A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

*Principal Investigator*

IOV-COM-202- A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

*Principal Investigator*

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 238)

*Principal Investigator*

CA209915- A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 915)

*Principal Investigator*

CL-CA-P01-Phase III, Randomized, Double-Blind, Multicenter Trial Of Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells (NBS20) Vs. Autologous Peripheral Blood Mononuclear Cell Control (MC), Both Coadministered With Adjuvant GM-CSF, For The Treatment Of Patients With Metastatic Melanoma

*Principal Investigator*

CA017-055- A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated

*Principal Investigator*

2125-MEL-301- A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

*Principal Investigator*

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.

*Principal Investigator*

CA209218 - Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Subjects with Unresectable or Metastatic Melanoma

*Principal Investigator*

CA209-238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 238)

*Principal Investigator*

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

*Principal Investigator*

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

*Principal Investigator*

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

*Principal Investigator*

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

*Principal Investigator*

LX1606-303: A Phase 3, Randomized, Placebo-controlled, Multicenter, Doubleblind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

*Principal Investigator*

NSABP MPR-1 - NSABP Patient Registry and Biospecimen Profiling Repository

*Principal Investigator*

STX0112 - Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres,™ microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study

*Principal Investigator*

BT-CL-PGG-CRC1031 - A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer

*Principal Investigator*

IMMU-130-02- A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer

*Principal Investigator*

GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen

*Principal Investigator*

IMMU-132-01 - A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

*Principal Investigator*

NSABP FC-7 - A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

*Sub Investigator*

PACE Clinical trial RCT using Bone Marrow Stem Cells in Patients with Severe PVD  
Bone marrow Harvest

*Sub Investigator*

050012: A Phase I/II Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients with Solid Tumors

*Sub Investigator*

CA184-338 - A MULTI-SITE RETROSPECTIVE OBSERVATIONAL STUDY OF US PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA RECEIVING IPILIMUMAB (YERVOY®) AS FIRST-LINE THERAPY

*Sub Investigator*

2009-0288 - Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients

*Sub Investigator*

CA209-037 - A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.

*Sub Investigator*

TPU-TAS-102-301 - RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES

*Principal Investigator*

Cooperative group study - SWOG Study Phase III Prospective RCT comparison of Octreotide plus Interferon alpha vs Octreotide plus Bevacizumab in advanced poor prognosis carcinoid patients. 5/2012

*Principal Investigator*

ET743-SAR-3007 - "A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma". Janssen Research and Development LLC

*Sub Investigator – Bone Marrow Harvest*

AMORCYTE PreSERVE A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction.

*Sub Investigator*

CA184-240 - A Single Arm Open-Label Phase II Study of Vemurafenib Followed by a Continuous Administration of Ipilimumab in Subjects with Previously Untreated V600 BRAF Mutated Advanced Melanoma

*Sub Investigator*

103A-301- A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (MAVIS= Melanoma Antigen Vaccine Immunotherapy Study).

*Sub Investigator*

ECOG E1609- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma. Eastern Cooperative Oncology Group

*Sub Investigator*

SWOG S1005- A Phase II Study of MK-2206 (NSC-749607) as a Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer. SWOG

*Sub Investigator*

NCCTG N0949- Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer. North Central Cancer Treatment Group

*Sub Investigator*

RTOG 0848 - A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. RTOG

*Sub Investigator*

C80702 - A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. Southwest Oncology Group

*Sub Investigator*

IMCL CP15-0806: A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRalpha Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue. ImClone Systems Inc.

*Sub Investigator*

BIOVEX 005A- Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease. BIOVEX

**Presentations**

Core Lecture Speaker – Malignant Melanoma 2011- Present  
Core Lecture Speaker – Neuroendocrine Malignancies 2012 – Present  
Core Lecture Speaker – Bone sarcomas 2014 – Present  
Core Lecture Speaker – Soft Tissue sarcomas 2014 - Present  
NCAN Speaker "Medical Management of NET disease" 3/2015  
CNET Speaker "NET associated Diarrhea" 8/2014

CNET Speaker "Medical Management of Pancreas and Bowel NET" 8/2013  
Health Central "Skin Malignancies" 12/2013  
Grand Rounds at MDACCO "Current Management of Neuroendocrine Tumors" 11/2012  
Journal Club Anti PDI and Anti PDI ligand Phase I studies from NEJM 6/2012 MDACCO  
Grand Rounds at MDACCO "Current Update in the Management of Melanoma" 9/2011  
Metastatic Breast Cancer 4/2011  
Journal Club "JCO 2010 Paper on MSI in Colon Cancer and Adjuvant Therapy" 5/2011  
Testicular Malignancies  
Sarcoma  
CNS Malignancies  
Bladder Cancer  
Metastatic Colorectal Cancer  
CRC Peritoneal Carcinomatosis  
NSCLC  
Journal Club: Brite Registry Data With Use of Bev Beyond 1<sup>st</sup> Progression  
Journal Club: HRPC Phase II with Samarium and Chemotherapy  
Medical Residents/Students/PA Lectures  
Lymphomas, Acute Leukemias, Chronic Leukemias, Plasma cell Dyscrasias, BM Failure  
Syndromes, Myeloproliferative Disorders, Lung Cancer, Anemia, NF, BMT,  
Leukocytosis, Peripheral Smears, Colon, Lung, GI, GU, Melanoma/Sarcoma,  
Head/Neck  
Board Review:  
ASCO-SEP, ASH-SAP, JCO Clinical Diagnosis, MD Anderson BR, HematoPath Lab, NCCN  
CME, ASCO VM, Jeopardy

### **References**

Dan Buchholz- CEO UFHCC Orlando Health 407-247-6192  
Omar Kayaleh - GI Med Onc Section Chief 407-716-2275  
Debu Bose - Chief of GI Surgical Oncology, Leader of Pancreas Center 407-462-5374  
Patrick Kelly - Radiation Oncology for GI Section 407-766-6307  
Carmen Allegra Chief of the Hematology Oncology Division - 352-219-1989

### **Conferences**

Melanoma Symposium New York 2015  
ASCO Chicago 2010, 2011, 2012, 2015  
Neuroendocrine Tumors Ottawa 2012  
Sarcoma and GIST Milan 2012  
GI ASCO Symposium San Francisco 2012, 2013, 2014  
Melanoma Symposium Tampa 2011  
NANET Conference San Diego 2012, Charleston 2013, Tennessee 2014  
NCCN Hollywood 2013

### **Hobbies & Interests**

Piano, basketball, ultimate frisbee, finance, real estate

### **Board Review**

#### **2011-2012 MDAnderson HemOnc Fellow Board Review**

Aug Breast  
Sept Lung, HNC  
Oct Melanoma/Sarcoma, CDO  
Nov GU I/II  
Dec GI I/II  
Jan BioStatistics  
Feb CNS, CDO  
March Gyn I/II  
April Pharmacology I/II

May Molecular Biology, CDO  
June Epidemiology/Supportive Care, BMT

### **2010-2011 University of Florida Fellow Board Review**

Breast Cancer Cases with Dr Heldermon (Onc)  
BMT Jeopardy  
Clinical Diagnosis in Oncology (JCO)  
HematoPath Lab Acute Leukemias  
Hematology Meds Part II with Dr Zumberg (Hem)  
IMER Mantle Cell Lymphoma  
Hemolytic Anemia with Dr Zumberg (Hem)  
Transfusion Jeopardy  
IMER Ovarian Cancer  
Molecular Biology/Genetics Jeopardy  
HematoPath Lab Low Grade Lymphomas  
Normal B Cell Development with Dr Winters (Immuno)  
IMER Prostate Cancer with Dr Blake  
"Skin Manifestations with Internal Malignancies" with Dr Mitchell (Derm)  
Anemia Jeopardy (Dec 2010)  
IMER MM and SCT (Jan 2011)  
Jay Lynch's Re-hASH (Lymphoma) (Jan 2011)  
Bleeding Disorder Jeopardy (Jan 2011)  
HematoPath Lab Aggressive Lymphomas (Jan 2011)  
Clinical Diagnosis in Oncology (Feb 2011)  
"I have AIDS and I'm Pregnant" Jeopardy (Feb 2011)  
IMER CLL (Feb 2011)  
Gyn Malignancies/Testicular Jeopardy (March 2011)  
IMER CML (March 2011)  
Breast Ca Jeopardy (April 2011)  
"Rare/Uncommon Malignancies" Jeopardy (May 2011)

### **2009-2010 University of Florida Fellow Board Review**

2009

Peripheral Smears: Red Cells/Thrombocytopenia Part I  
Peripheral Smears: Red Cells/Thrombocytopenia Part II  
Peripheral Smears: Malignant Hematology with Graham  
ASCO/NCCN Cetuximab Reaction Iman/Sajeve  
Hemophilia/Hematology Part II Dr Zumberg  
ASH - MDS with Cogle  
Oncotype Dx with Karen Daily  
ASH - Lymphoproliferative disorders, MJ/Lynch/Dang  
Carcinogenesis/Molecular Biology Part I- Bennett  
Carcinogenesis/Molecular Biology Part II- Bennett  
IMER DLBCL Dr Flynn  
ASH - Hemolytic Anemia/Dr Zumberg  
Dang - Informal talk on Mantle Cell and T cell Lymphoma  
Common Skin Infections in Immunocompromized Patients with Dermatology Dr Mitchell  
Thalassemia/Sickle cel q's with Dr Lottenberg  
IMER MDS  
IMER: Multiple Myeloma  
ASH-SAP Transfusion Medicine  
Carcinogenesis/Molecular Biology Part III - Bennett Part III  
ASH-SAP Plasma cell dyscrasia with Dr Moreb  
MD Anderson Review Benign Hematology  
Hematopath Lab Acute Leukemia  
ASH-SAP Myeloid Disorders with Fletcher  
MD Anderson Review Malignant Hematology  
ASH-SAP Hemostasis/Thrombosis

2010

ASH-SAP Iron Metabolism, Acquired Anemia

IMER: Breast Cancer  
IMER: Melanoma  
Hematopath Lab Benign LAD, Low Grade Lymphoma  
Hematopath Lab Aggressive Lymphomas  
IMER: Renal Cell Carcinoma  
Dr Lynch "Best of ASH Lymphoma"  
IMER CML  
ASCO SEP Breast Cancer QA  
Hematopath MDS subtypes/Myeloproliferative  
BAC Julia  
ASCO SEP Sarcoma/Melanoma  
HematoPath Lab Plasma cells/Masto/Eosino/etc Graham  
ASCO SEP GynOnc with MJ  
Dr Grosbach's "Potpourri of Blood Smears"  
GU ASCO-SEP Jeopardy  
Diagnosis in Oncology JCO  
Dr Gopalan's "Carcinoma of Unknown Primary"  
Dr Siddiqui's "Rare Tumors"  
Dr Kim Liver Transplant Hepatobiliary Malignancies  
Dr Pennypacker End of Life Care  
Head/Neck ASCO-SEP Jeopardy